Publication | Closed Access

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

MedicineCancer ManagementGynecologyRecurrent Ovarian CancerPolymerase Inhibitor OlaparibCancer TreatmentOncologyRadiation OncologyOvarian CancerOral Poly